A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee

Trial Profile

A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs GSK-3858279 (Primary) ; GSK-3858279 (Primary)
  • Indications Pain
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jun 2018 Planned End Date changed from 13 Nov 2019 to 27 Nov 2019.
    • 01 Jun 2018 Planned primary completion date changed from 13 Nov 2019 to 27 Nov 2019.
    • 01 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top